Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Corn futures chart.
http://futures.tradingcharts.com/chart/CN/M
Looks Like a classic Head and shoulders.
Chart Readers, what is on the horizon for Corn ?
Greedy. You Can't Stop a Speeding 3rd Gen Freight Train
In Response to your Post 66197. I feel privaliged to have Corn Farmer representation on this board and consider you a valuable asset. How did the Corn Harvest go this year ? Are Prices stable ?
Are Corn Farmers in your Community Concerned with BioDiesel Subsidies being redirected to Algea ? Do you think that a change in policy is in the works ?
I've been tracking Corn futures to learn if the Market is adjusting to Obama moving away from Corn for Fuel.
http://futures.tradingcharts.com/chart/CN/M
Gallons of oil per acre per year
Corn 18
Soybeans 48
Safflower 83
Sunflower 102
Rapeseed 127
Oil Palm 635
Micro Algae 5000-15000
I better understand your sentiment toward Algea Companies after learning the Superior yield that Algea offers. Is anyone in the Corn Community considering a shift to bioCentrics low cost Algea BioReactor in the event subsidies are removed by Obama ? Have you recommended any of the Colleges that now offer BioCentric Training ? Is anyone getting on board with Superior 3rd Generation Algea Crops (5000-15000 Gal/acre yields) ? With every MegaTrend shift comes an extraordinary Opportunity. Stay Positive. Embrace the change.
GM . I use to read through your posts but lately I just read the first line and hit next.
I'm just not finding anything of any value.
Are Corn Farmers in your community migrating to Algea ? What about you ?
Gallons of oil per acre per year
Corn 18
Soybeans 48
Safflower 83
Sunflower 102
Rapeseed 127
Oil Palm 635
Micro Algae 5000-15000
Phloyd. I too find 2010 target for 5 Million Low
When we've had a 6 Million order in Production for 2 months
Along with a list of opportunities that could amount to a few more million + Pop in opportunities not known at this time.
But I like a CEO who Underpromises and Overdelivers, so I'm ok with 5 Million for now.
$ 5M / 710 M Shares = .007 x PE 15 = 10.5 cents
$ 10M / 710 M Shares = .014 x PE 15 = 21 cents
RWE working with Who ? to get cost down to $1000/ KW capacity.
Solar power can be as much as $8 per watt or $8,000 p/KW and as low as $3,500 p/KW capacity (capacity, I mention is the capital cost to build the facility); wind $3,500 p/KW capacity ... however, wind generators are not the best technology everywhere, especially low wind areas.
Algae ... at least RWE is closer to $2,500 p/KW capacity. We are working hard to reduce this to under $1,000 and we, unlike wind and solar, can consume the Nox and CO2 produced by existing coal fired generation plants. The limit to how much energy can be produced with algae is land mass, which to replace all imported oil would require approximately 17 million acres; however there are in New Mexico and Arizona alone about 48 million acres of land that is not used or cannot be used for farming, which makes it ideal for our systems.
Maybe BEHL ? Just kidding, we know it's BEHL
GM. Are the Corn Farmers in your Community Migrating to Algea ?
Gallons of oil per acre per year
Corn 18
Soybeans 48
Safflower 83
Sunflower 102
Rapeseed 127
Oil Palm 635
Micro Algae 5000-15000
Looks like a lucrative opportunity for those who adapt early
GM . Let the light shine through in your Soul
Will you be in Las Vegas for the conference ?
She's coming around.
She's loaded her boat and wants to see this run just as much as us.
She's going to give BEHL the benefit of hitting targets this month.
She's with us this time
The push has been going on for 5 days .
Some good lessons on chart reading on-line.
You'll get there. Stay positive.
GM. Only Fools Short January
Welcome aboard. I like your new positive BEHL attitude.
Hold your shares this time.
You would be wise to hold your shares this time GM.
Just the beginning of a January Effect Run
30 days +1
Clowns Silent. Hot Water Tap Turned ON.
Letting her Sheep run wild
Great Volume today. Anxious Buyers.
Temperature rising in LV
GM when the stock reaches 5 dollars and is listed on the Nasdaq
all the barriers that you speak of will have been removed and it will be safe for you to buy. In the interiim, many of us clearly understand the risk with a 1 cent stock, understand we are in an emerging Megatrend sector, and can see accelerated progress and growth with this little gem.
I can hardly contain my excitement.
I truly believe your expectations for a penny play are unrealistic and you should move to something that satisfies your requirements. Your wasting your valuable time here.
Let us enjoy those 3000% to 6000% gains. Find yourself a nice safe place to invest.
GM. Read their latest PR for Specific Dates
Your posts are more ridiculous with the passing of each day.
Follow me to the Algea $EA
BP Invests 10 Million in Martek Algea
http://www.oilgae.com/blog/2009/08/bp-invests-10-million-in-martek-algae.html
Big Players Investing in this Sector
Apples to Apples PE 15
Martek Biosciences: Can It Turn Algae into Gold, Or at the Least Oil? 4 comments
October 30, 2009 | about: BP / MATK
Beacon Asset Managers
Follow
126
Followers 17
Following
About this author:
Profile & More Articles
Visit: Beacon Asset Management
Font Size: Print EmailTweetThis
Martek Biosciences Corp. (MATK) is a global leader in the production of docosahexaenoic acid from microalgae and arachidonic acid from fungus, and as such stands to benefit from the combined U.S. demographics of an expected uptick in U.S. births, aging baby boomers and an apparently health-conscious Generation Y.
“Wait a minute! Docosahex-what? Arachid-what? Made from microalgae? Fungus? And, what does this have to do with babies, teenagers and the soon-to-be elderly?”
Docosahexaenoic acid, or DHA as its more commonly referred to, is one of the primary omega-3 fatty acids, the same omega-3s that have become all the rage as a food supplement due to their purported health benefits for the heart, brain, eyes and infant development. Arachidonic acid–ARA–is an omega-6 fatty acid that is considered an “essential fatty acid” crucial for muscle and skeletal repair and growth, and, along with DHA, considered a key component neurological development and maintenance.
The health benefits of omega-3s and in particular DHA emerged in the 1970s with a study of Greenland Eskimos who consumed large amounts of fatty seafoods, but displayed virtually no incidence of heart disease. In 2004, the U.S. Food and Drug Administration (FDA) gave DHA “qualified health claim” status that research is supportive, though not conclusive” that its consumption may “reduce the risk of coronary heart disease.”
Other studies determined that DHA and ARA were crucial in brain, eye, muscle and skeletal development in babies. Meanwhile researchers have also determined that DHA may inhibit plaque development in the brain thought to be responsible for Alzheimer’s disease, and there are indications that DHA may inhibit the growth of some cancers. Research of these health benefits and others with both DHA and ARA are ongoing, with one of the largest being a U.S. National Institutes of Health study to evaluate DHA in Alzheimer’s disease.
A primary source of DHA and other omega-3s is fish oils, and fish oil as an omega-3 and DHA dietary supplement essentially went mainstream in the late 1990s as their apparent health benefits become widely known. Fish receive their DHA intake from algae, and scientists with Martin Marietta (which merged with Lockheed (LMT) in 1995)who were researching the beneficial use of algae in long-term space flight, spun off from their parent company and developed and patented the methods for deriving DHA from algae, and ARA from a fungus.
These scientists formed Martek Biosciences in 1985, brought the company public in 1993, and introduced their first DHA and ARA infant formula in 1995 in Belgium, and received FDA clearance for its use in U.S. infant formulas in 2001.
Martek’s core product application remains DHA and ARA as a supplement in infant formulas. Sales of Martek DHA/ARA for infant formulas have more than doubled since 2003, climbing from less than $150 million in 2003 to $300 million in 2008. The company claims 99 percent penetration of the U.S. market, which it views as a “$170 million to $190 million market opportunity;” and 40 percent penetration of the international market, which it pegs as a $300 million to $325 million market opportunity, with the primary future growth driver being Asia. Martek considers consumer demand for infant formula as “stable despite the weak global economy.”
The company’s secondary product application–DHA supplements and additives for adults–has also seen robust growth, with sales climbing from about $11.5 million in 2006 to an estimated $38 million for 2009. Martek sees growing sales across all segments of this market in the years ahead, and believes there will be increasing consumer awareness about the health benefits of DHA.
The company should see increased future sales based on demographics. Although it already has all but complete penetration of the U.S. market for infant formulas, The number of women entering their key child-bearing years is set to increase by roughly 250,000 per year for the next 10 years as the large cohort of Generation Y replaces the much smaller Generation X. Along with more of them, Gen. Y is commonly believed to be much more health conscious with relation to food than members of Gen. X and the Baby Boom. This should be a boon to Martek’s sales of DHA/ARA supplements to pregnant and nursing mothers, as well as to DHA/ARA supplements for other adults.
And as the large cohort of Baby Boomers age their interest in health supplements will undoubtedly increase. The more evidence they hear supporting DHA’s health claims regarding Alzheimer’s Disease, coronary heart disease and cancer, the more money they will pour into DHA supplements, and the more likely that they will purposely purchase products (currently more than 50 and growing) containing Martek’s patented “life’sDHA.”
While the company would appear to be a two-trick pony, it recently entered into a joint development agreement with BP plc. (BP) Biofuels to produce microbial oils for use in the biofuels industry. The goal of the agreement is to “establish proof of concept for large-scale, cost effective microbial biodiesel production through fermentation.” BP committed $10 million to the initial phase of the collaboration, under which BP will own any new intellectual property developments, with Martek receiving exclusive license for application and commercialization in nutrition, cosmetic and pharmaceutical applications. While this agreement adds nothing to the bottom line in the near, or even mid, term, Martek scientists proved visionary in the past, and certainly have the wherewithal to discover new products and applications through this project.
The share price is well off its all-time high of about $67 hit in early 2005, and down about 70 percent from its 52-week high of $31.60. The share price has declined about 40 percent since early September after recording a 12 percent year-over-year decline in quarterly revenues caused by retail companies de-stocking old inventories of infant formulas. Martek executives projected strong fourth-quarter 2009 and full-year 2010 revenues, on anticipated increasing sales in both infant formula and adult products.
In our opinion, one problem with valuing Martek, is does one value the shares on a food company or a biotech company basis? Being conservative, we believe a company should be valued on its growth prospects. Martek sells on an October 2009 consensus P/E of 15.1. This falls to 13.1 on a consensus forecast for October 2010. However, the forecast for 2010 earnings per share vary enormously, with the highest being $1.80 and the lowest $1.28 and consensus of $1.40.
Therefore, we believe the shares are attractive given the revenue growth potential in its adult market products, strong cash flow, improving demographics, and the company’s stated goal of improving gross margins. We feel that the company should earn between $1.40 and $1.50 per share for the year ending October 2010.
The company is expected to report fourth 2009 quarter earnings between Dec. 11-16. Consensus estimates call for earnings per share of $0.33.
click to enlarge
Let's do 5M 2010
Doesn't make sense considering they have a 6M order in hand plus all the other things listed in their PR but , what the heck, let's do an Ultra Ultra Ultra Conservative Estimate with 5M
5M / 710 M = .007 x 15PE (Martek) = 10.6 cents
I'll take 1000%
If 5 M didn't happen in 2009
should we roll it into 2010 for 25 -30 M ?
15 M / 710 M shares =.021 / sh x 15 PE ( Martek ) = 31.6 cents / share
20 M / 710 M = .028 x 15 = 42.3 cents
25 M / 710 M = .0352 x 15 = 52.8 cents
30 M / 710 M = .0423 x 15 = 63.4 cents
I see a 30 Bagger ( 3000% ) @ Low end 15 M
and a 60 Bagger (6000%) @ High end 30 M
Anyway you cut it, it's got to be better than 2 % in the bank
Solid Green Day
BEHL - BIOCENTRIC ENERGY HO (OTC)
[ Daily Quotes ] [ Weekly Quotes ] [ Monthly Quotes ]
Date Open High Low Last Change Volume % Change
01/04/10 0.0120 0.0125 0.0100 0.0120 +0.0020 5534956 +20.00%
12/31/09 0.0090 0.0100 0.0090 0.0100 +0.0008 3466800 +8.70%
12/30/09 0.0090 0.0095 0.0086 0.0092 +0.0002 4429500 +2.22%
12/29/09 0.0095 0.0095 0.0090 0.0090 -0.0005 3422700 -5.26%
12/28/09 0.0091 0.0100 0.0090 0.0095 +0.0005 5979900 +5.56%
http://stockcharts.com/h-sc/ui?s=BEHL&p=D&b=5&g=0&id=p55818206857
Recent Trades - Last 10
Time Ex Price Change Volume
15:53:23 Q 0.012 +0.002 20,000
15:52:28 Q 0.0115 +0.0015 70,000
15:50:25 Q 0.0115 +0.0015 5,000
15:46:10 Q 0.012 +0.002 6,333
15:45:46 Q 0.012 +0.002 7,000
15:29:12 Q 0.012 +0.002 25,000
15:26:01 Q 0.012 +0.002 50,000
15:13:57 Q 0.012 +0.002 131,000
15:13:29 Q 0.012 +0.002 50,000
15:13:29 Q 0.012 +0.002 100,000
USS Enterprise is leaving Shore
All aboard. Nice Volume. Nice Price surge.
You're probably already a Millionaire @ .001
Sit back, Relax ( I love what is happening ) Multi Millionaire is next leg up for you.
Patients Milehigh. Everything is Aligning Beautifully.
The Biodiesel Tax Credit problem will accelerate the push to algea as a feedstock.
BioCentric is positioned beautifully with their 2nd Gen, Low Cost, Commercial Ready system.
It doesn't get any better than this.
Envirotek bought the land but that the pbrs were temporarily on hold
ENTK most likely waiting for 2nd Gen to arrive.
ENTK survival is geared to Algea.
DF wouldn't post 20 Acres if he wasn't confident the order was rock solid.
30 days + 1. The January Effect
Constant Buying Pressure throughout January.
IT (They) have gone silent. Just Like Clockwork.
Mile High. ENTK needs a Low Cost Algea Solution
more than ever to be self sustaining and non reliant on Tax Credits.
Biocentric is the path to their Survival and hopefully other suffering Biodiesel Plants will recognize the emense opportunity BioCentric offers with the lowest cost BioReactor on the Planet.
There could be some amazing surprises this year.
Milehigh. I would say 20 Acres with ENTK is in the Bag.
If you watch the video's, there are strong indications they intend to Migrate to Algea as a feedstock and use the Biocentric solution. I Believe I saw a Biocentric Decal on their Entrance window. They probably have a license agreement to sell Biocentric systems to enhance Mini Refiner Sales. Just a guess but I think these 2 companies have a strong symbiotic alliance.
Phloyd. 18 desktops. Geared for College Demonstration systems ?
BEHL Seeds being planted with our Youngest and Brightest across the country.
Marketing Machine is rolling.
DF wil blow the roof off 5 million 2010 Target with
6 million Pharma / Nutra order in production PLUS +++++++++
ALL THIS ADDITIONAL REVENUE. CAN ANYONE PLACE A PRICE ON IT ?????
Projected Sources of Revenue for 2010
1) 18 "Desktop" Continuous Flow Photobioreactors in year 1 ( ? )
2) 24 "Wall Unit" Photobioreactors in year 1 ( ? )
3) 36 "Culturing Systems" in Year 1 ( ? )
4) 20 Acres of Algae Pro Photobioreactors in year 1 ( 86K x 20 = 1.7 M)
5) Management Contract for 20 Acres of Algae Pro Photobioreactors in year 1 ( ? )
6) Commission for the sale of production of 20 Acres of Algae Pro Photobioreactors in year 1 ( ? )
Under promise / Over Deliver .
6 M + 1 (?) + 2 (?) + 3 (?) + 4 (1.7M) + 5 (?) + 6 (?) = 7.7 M + + + + + ( Additional Surprises Enroute)
I like it a lot !
I'd be disappointed if the company wasn't doing everything possible to promote themselves.
1M shares is a drop in the bucket for all the play time we're getting.
It's part of the recognition process and it's transparent.
Go BEHL
A Green Week ! Imagine that
the tide is turning people.
http://quote.barchart.com/quote.asp?sym=behl&code=BSTK
Anyone know the date that SC Harvester turns on ?
Doesn't matter if we have 3 PBR's cranking product.
The Bottleneck is the Harvester(s)
I assume we'll install a Harvester on the West Coast too, or do we ship unfinished product to SC for processing ?
expedited production of the existing orders.
= expedited production of revenue
I like these words a lot
Sellers turn Buyers on Monday.
Shares are now with strong hands who have no intention of selling at these low levels.
January Buyers will be fighting for our Shares.
Happy New Year Longs ! Perfect Storm brewing for this little gem.
What about a "Wall" of mirrors positioned in the sunny zone to concentrate sunlight ?
What the heck is a "Wall" in their latest PR's ?
Vertical Stacked 2nd Gen RWE Hybrid system ? Concentrated Light System?
Anyone ?
Thanks Lonsenior. I truly believe we are experience a Tax Loss selling Flush
2010 will be BioCentric's defining / explosive year.
A few exterior LED Lamps could easily fix this problem
If it is a problem and keep Algea growing 24 / 7